tbuckley/cabot-search huggingface dataset:
Leukemia Homotransplants in Mice&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Stewart, Sarah E.
Journal: JNCI Journal of the National Cancer Institute (1954)

Journal Article Leukemia Homotransplants in Mice Get access Sarah E. Stewart Sarah E. Stewart National Cancer Institute,3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 14, Issue 5, April 1954, Pages 1187–1193, https://doi.org/10.1093/jnci/14.5.1187 Published: 01 April 1954 Article history Received: 08 October 1953 Published: 01 April 1954
Clinical severity and molecular characteristics of circulating and emerging rotaviruses in young children attending hospital emergency departments in France
Authors: A. de Rougemont, J. Kaplon, C. Fremy, M.-C. Legrand-Guillien, A. Minoui-Tran, C. Payan, A. Vabret, L. Mendes-Martins, M. Chouchane, R. Maudinas, F. Huet, F. Dubos, D. Hober, M. Lazrek, C. Bouquignaud, A. Decoster, S. Alain, J. Languepin, Y. Gillet, B. Lina, Y. Mekki, F. Morfin-Sherpa, A. Guigon, J. Guinard, V. Foulongne, M. Rodiere, V. Avettand-Fenoel, S. Bonacorsi, A. Garbarg-Chenon, D. Gendrel, P. Lebon, M. Lorrot, P. Mariani, J.-F. Meritet, A. Schnuriger, G. Agius, A. Beby-Defaux, D. Oriot, R. Colimon, G. Lagathu, O. Mory, S. Pillet, B. Pozzetto, J.-L. Stephan, S. Aho, P. Pothier
Journal: Clinical Microbiology and Infection (2016)
Studies on Mouse Lymphomas. II. Behavior of Three Lymphomas in Diffusion Chambers in Relation to Their Invasive Capacity in the Host
Authors: Emma Shelton, Mary E. Rice
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Studies on Mouse Lymphomas. II. Behavior of Three Lymphomas in Diffusion Chambers in Relation to Their Invasive Capacity in the Host Get access Emma Shelton, Emma Shelton Laboratory of Biology, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Mary E. Rice Mary E. Rice Laboratory of Biology, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 21, Issue 1, July 1958, Pages 137–161, https://doi.org/10.1093/jnci/21.1.137 Published: 01 July 1958 Article history Received: 07 January 1958 Published: 01 July 1958
Teaching and learning DSM-III
Authors: A E Skodol, R L Spitzer, J B Williams
Journal: American Journal of Psychiatry (1981)

This article presents recommendations for training programs in DSM-III to help counter feelings of apprehension expressed by many mental health professionals over the transition to the new nomenclature and its multiaxial evaluation system. The authors suggest educational objectives, didactic curricula, and methods for training in the clinical application of DSM-III and discuss supervising the use of DSM-III in patient intake and evaluation. Thorough mastery of DSM-III should not be expected after a limited program; learning its strengths and limitations will be a continuing process.
Quantitative Studies on the Latent Period of Tumors Induced with Subcutaneous Injections of the Agent of Chicken Tumor I. I. Curve Relating Dosage of Agent and Chicken Response
Authors: W. Ray Bryan
Journal: JNCI Journal of the National Cancer Institute (1946)

Journal Article Quantitative Studies on the Latent Period of Tumors Induced with Subcutaneous Injections of the Agent of Chicken Tumor I. I. Curve Relating Dosage of Agent and Chicken Response Get access W. Ray Bryan W. Ray Bryan senior biologist National Cancer Institute, National Institute of Health, United States Public Health Service1 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 4, February 1946, Pages 225–237, https://doi.org/10.1093/jnci/6.4.225 Published: 01 February 1946
Clinical and Experimental Findings After Five Years' Treatment of Diabetes with Sulfonylureas
Authors: H MEHNERT
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genetic characterization of human bocavirus among children with severe acute respiratory infection in China
Authors: Yanqun Wang, Yamin Li, Jun Liu, Yanjie Zhao, Zhengde Xie, Jun Shen, Wenjie Tan
Journal: Journal of Infection (2016)

To investigate the genetic character of Human bocavirus (HBoV) among children with severe acute respiratory infection (SARI) in China.We screened 993 respiratory samples for HBoV by PCR among hospitalized children with SARI between September 2007 and March 2014. Four of HBoV1 samples were selected for complete genomes analysis by next-generation sequencing.The results show that 200 (20.1%) out of 993 samples were HBoV-positive, most of these HBoV belong to HBoV1 subtype (n = 197), HBoV2 (n = 1) and HBoV3 (n = 2) were also detected. Fifty (5.04%) of 993 SARI patient were detected as HBoV-positive only. Four HBoV1 genomes in this study were conserved and showed no significant difference among the nucleotide diversity from different regions. Analyses of evolutionary rates showed that NS1 exhibited the highest degree of conservation while the VP1 gene exhibited the fastest rate of evolution at 4.20 × 10(-4) substitutions/site/year. The nucleotide deletions and substitutions occurred in NP1 and VP1 represented novel molecular signatures enabling subtype differentiation between HBoVs.We described some new characteristics in the epidemiology of HBoV among children with SARI, these data will significantly expand the current knowledge of HBoV epidemic and genomic characterization among children with SARI.
Demonstration of the Intracellular Location of Rous Sarcoma Virus Antigen by Fluorescein-Labeled Antiserums
Authors: Richard A. Malmgren, Mary A. Fink, Willie Mills
Journal: JNCI Journal of the National Cancer Institute (1960)

Intracytoplasmic fluorescent material was demonstrated in the cells of the Rous sarcoma by means of fluorescein-labeled anti-Rous sarcoma virus serums. In addition, an occasional cell contained an intranuclear fluorescent body. The number of sarcoma cells containing the fluorescent material was related to the amount of virus inoculated into the chicken to initiate the tumor. The fluorescence was not seen in the cells of normal chicken tissues exposed to the fluorescein-labeled anti-Rous sarcoma virus serums. Prior treatment of the Rous sarcoma tissue, containing virus with unlabeled antiviral serums, blocked the reaction between the intracytoplasmic and intranuclear antigen and the fluorescein-labeled antivirus serums. These findings are interpreted as demonstrating intracytoplasmic and intranuclear virus or viral-associated antigen in cells infected with the Rous sarcoma virus.
Responses of Strain DBAf/2 Mice, Without the Mammary Tumor Agent, to Oral Administration of Methylcholanthrene
Authors: Howard B. Andervont, Thelma B. Dunn
Journal: JNCI Journal of the National Cancer Institute (1953)

Journal Article Responses of Strain DBAf/2 Mice, Without the Mammary Tumor Agent, to Oral Administration of Methylcholanthrene Get access Howard B. Andervont, Howard B. Andervont Search for other works by this author on: Oxford Academic PubMed Google Scholar Thelma B. Dunn Thelma B. Dunn Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 14, Issue 2, October 1953, Pages 329–339, https://doi.org/10.1093/jnci/14.2.329 Published: 01 October 1953 Article history Received: 03 June 1953 Published: 01 October 1953
Reducing Periconceptional Methylmercury Exposure: Cost–Utility Analysis for a Proposed Screening Program for Women Planning a Pregnancy in Ontario, Canada
Authors: Janet Gaskin, Colin Rennie, Doug Coyle
Journal: Environmental Health Perspectives (2015)

The assessment of neurodevelopmental effects in children associated with prenatal methylmercury exposure, from contaminated fish and seafood in the maternal diet, has recently been strengthened by adjustment for the negative confounding resulting from co-exposure to beneficial polyunsaturated fatty acids (PUFAs).We aimed to determine the cost-effectiveness of a periconceptional screening program of blood mercury concentration for women planning to become pregnant in Ontario, Canada. Fish intake recommendations would be provided for those found to have blood mercury levels above the intervention threshold.Analysis was conducted using a combined decision tree/Markov model to compare the proposed screening intervention with standard care from a societal perspective over a lifetime horizon. We used the national blood mercury distributions of women 20-49 years of age reported in the Canadian Health Measures Survey from 2009 through 2011 to determine the cognitive deficits associated with prenatal methylmercury exposure for successful planned pregnancies. Outcomes modeled included the loss in quality of life and the remedial education costs. Value of information analysis was conducted to assess the underlying uncertainty around the model results and to identify which parameters contribute most to this uncertainty.The incremental cost per quality-adjusted life year (QALY) gained for the proposed screening intervention was estimated to be Can$18,051, and the expected value for a willingness to pay of Can$50,000/QALY to be Can$0.61.Our findings suggest that the proposed periconceptional blood mercury screening program for women planning a pregnancy would be highly cost-effective from a societal perspective. The results of a value of information analysis confirm the robustness of the study's conclusions.
Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery
Authors: Yong-il Kim, Hai-Jeon Yoon, Jin Chul Paeng, Gi Jeong Cheon, Dong Soo Lee, June-Key Chung, E. Edmund Kim, Woo Kyung Moon, Keon Wook Kang
Journal: Clinical Nuclear Medicine (2016)

Purpose We performed pretreatment angiogenesis imaging (68Ga-NOTA-arginyl-glycyl-aspartic acid [RGD] PET/CT) to compare its prognostic value to dynamic contrast-enhanced (DCE) MRI in breast cancer patients. Methods Forty-four female patients with stage II or III breast cancer (aged 47.3 ± 8.1 years) were prospectively enrolled and underwent 68Ga-NOTA-RGD PET/CT and DCE-MRI imaging. All patients received neoadjuvant chemotherapy and underwent surgery. With pretreatment 68Ga-NOTA-RGD PET/CT, SUVmax of the tumor in the torso (-T) and regional (-R) images were measured. With pretreatment DCE-MRI, the largest diameter of the tumor and maximum enhancement index (EImax; EImax = [highest signal / baseline signal] − 1) of the tumor were assessed. Results Ten patients (22.7%) were found to have breast cancer recurrence after 17.9 ± 11.2 months. The SUVmax-R (P = 0.017, cutoff >2.79) of 68Ga-NOTA-RGD PET/CT, the largest diameter of tumor (P = 0.017, cutoff >6.3 cm), and the EImax (P = 0.008, cutoff >5.38) of DCE-MRI showed significant results by univariate analysis. The 3-year disease-free survival of SUVmax-R was 91.7% versus 59.1% by Kaplan-Meier analysis (hazard ratio, 5.379). Multivariable analysis demonstrated that SUVmax-R with tumor diameter or EImax were the significant parameters. In addition, the combined parameters of SUVmax-R and EImax revealed better predictive value for prediction of breast cancer recurrence (75.0%) than each parameter of SUVmax-R (64.2%) and EImax (68.7%). Conclusions Increased angiogenic activity of regional 68Ga-NOTA-RGD PET/CT (SUVmax-R) can be an early prognostic marker for the prediction of breast cancer recurrence.
An increase in reported cases of haemorrhagic fever with renal syndrome in Slovenia in early 2008
Authors: N Koren, E Grilc, M Blaško, T Avsic, A Kraigher
Journal: Eurosurveillance (2008)

Haemorrhagic fever with renal syndrome (HFRS) is an acute zoonotic viral disease, caused by hantaviruses. Hantaviruses infect rodents worldwide. They are transmitted to humans by aerosol from rodent excreta. Several hantaviruses are known to infect humans with varying severity.
The effects of National Health Insurance on Canadian Psychiatry: the Ontario experience
Authors: B Liptzin
Journal: American Journal of Psychiatry (1977)

After studying psychiatric coverage under national health insurance in Ontario, the author concludes that psychiatric benefits can be provided on the same basis as other medical benefits and that a government system can maintain confidentiality. Costs have been reasonable and in line with the proportion of psychiartists to the total number of physicians, and psychiartists' incomes have increased substantially, even with comparatively low official fees. Despite the existence of NHI, the public mental health system has been maintained in Canada and has been expanded in regard to children's services. There appears to be a continued need for direct public funding of services for certain other groups such as the elderly, chronic patients, ans substance abusers.
Survival benefits of zoledronic acid in patients with bone metastases from non-small cell lung cancer and high NTX levels: The role of BALP
Authors: J. E. Brown, V. Hirsh, P. P. Major, A. Lipton, R. J. Cook, C. J. Langer, M. R. Smith, R. E. Coleman
Journal: Journal of Clinical Oncology (2008)

19003 Background: In a clinical trial of zoledronic acid (ZOL) vs placebo in patients (pts) with bone metastases from solid tumors (not breast or prostate cancer; N = 773), ∼50% of pts had non-small cell lung cancer (NSCLC). Among all pts and NSCLC pts, ∼50% had high baseline levels of biochemical markers of bone resorption (N-telopeptide of type I collagen [NTX] ≥ 64 nmol/mmol creatinine) or formation (bone-specific alkaline phosphatase [BALP] ≥ 146 IU/L). Besides skeletal complication prevention, ZOL significantly prolonged survival in NSCLC pts with high baseline NTX, even after adjustment for other significant covariates (Hirsh V, et al. J Thorac Oncol. In press). However, the report did not include analyses by baseline BALP levels. Methods: Pts with NSCLC and bone marker data were included (n = 382), and analyses were performed by baseline NTX and BALP status. Kaplan-Meier survival estimates and Cox regression analyses of treatment by covariate interactions were performed. Results: In univariate analyses, variables associated with poorer survival were high pain score (P = .002), male sex (P = .020), low FACT-G score (P < .001), narcotic analgesics (P = .003), ECOG performance status > 1 (P < .001), high NTX (P = .003), high BALP (P = .020), creatinine ≥ 1.0 mg/dL (P = .032), and LDH ≥ 247 U/L (P = .005). In a multivariate model of treatment and baseline NTX and BALP, ZOL was associated with significantly increased survival vs placebo in the high-NTX subset (P = .02), but not in the high-BALP subset (P = .40). However, significant heterogeneity of benefits was detected between high- and low-BALP pts in the high-NTX subset (P = .04). Therefore, each group was assessed separately in Kaplan-Meier analyses. In the high-NTX subset, ZOL was associated with a 46% reduced risk of death in high-BALP pts (P = .006 vs placebo), but had no association with survival in low-BALP pts. ZOL was not significantly associated with survival in pts with low baseline NTX regardless of BALP status. Conclusions: Although prospective analyses are needed to elucidate the role of NTX and BALP, this analysis suggests that ZOL may prolong survival in a subset of NSCLC pts with advanced bone disease and high baseline levels of both markers. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Amgen Oncology, GTx Inc., Merck, Novartis Oncology, Novartis Pharmaceuticals Inc. Novartis Oncology, Novartis Pharmaceuticals, Inc. Novartis Pharmaceuticals Inc. Novartis Pharmaceuticals Inc. Novartis Pharmaceuticals Inc. - Speakers Bureau
Postoperative Fluid Therapy
Authors: G M Moss
Journal: New England Journal of Medicine (1968)

Each of these topics is relevant to all occupational groups.Whereas some of these projects might be beyond any single industry to fund, the Foundation can provide a formal mechanism, so that industrial organizations can combine forces and work with each other and with academic departments, to carry out a research project of common interest.There seem to be grounds for optimism that the British Occupational Health Research Foundation can attract funds, and can aspire to join the Association of Medical Research Charities.This association currently has 41 members, and the criteria for membership are that the principal activity should be medical research and the members should spend more than £250 000 per annum in the UK and use peer review in the allocation of grants and support for research.These principal 41 Medical Research Charities spent £170 million on medical research in 1989/1990.They cover every conceivable specialty that you can imagine, with one exception - Occupational Health.It is, therefore, high time that our own specialty had its own charitable foundation.The seeds that were sown at the Green College Symposiutm two summers ago have borne fruit.I am very pleased that The British Occupational Health Research Foundation became a registered charity on 5 June 1991 (Reg.No. 1003105).We have a splendid Board of Trustees
PWE-206 Pancreatic enzyme replacement therapy in pancreatic cancer- a role for the dietician
Authors: BC Yip, D Thorburn, H Doddaiah, S Subramaniam, K Besherdas
Journal: Gut (2015)

<h3>Introduction</h3> Pancreatic enzyme insufficiency (PEI) is a well-recognised cause of malnutrition in pancreatic cancer (PC). Pancreatic enzyme replacement therapy (PERT) in the form of enteric coated pancreatin microspheres is recommended in these patients with symptoms of PEI to prevent weight loss and malnutrition and improve quality of life. Given that the probability of PEI is high in PC (80–90%), PERT is recommended without the use of formal diagnostic tests. The optimal starting dose of PERT is 40–50000 lipase units per main meal. The aim of this study was to evaluate the use of PERT in PC patients, to ascertain if these patients were given the appropriate PERT dose and to determine whether dietician review was associated with more and better PERT use. <h3>Method</h3> A single centre retrospective analysis of patients diagnosed with PC in 2014 in a tertiary hospital specialising in the treatment of patients with hepato-pancreato-biliary (HPB) diseases. We identified 80 patients with PC. Information was collected from electronic patient records regarding the patients' symptoms of PEI, evidence of PERT use, the dose prescribed and whether the patients were seen by a dietician. Fisher's exact test was used to calculate whether (a) dietician review was associated with higher rate of PERT use and (b) dietician review was associated with higher rate of appropriate PERT dosing. <h3>Results</h3> Symptoms of PEI (abdominal pain, weight loss or steatorrhoea) were recorded in 57.5% of PC patients (46/80). PERT was prescribed in the minority of patients [41.3% (33/80)] with appropriate dosing given to the majority of patients when prescribed [66.7% (22/33)]. A dietician was involved in the care of less than half [43.8% (35/80)] of patients. However, referral to a dietician was strongly associated with PERT use with 60% (21/35) of patients being referred given PERT compared to only 26.7% (12/45) of patients who were not (p = 0.003). Dietician involvement was also associated with more appropriate PERT use with 85% (17/20) of patients given appropriate doses compared to 45.5% (5/11); (p = 0.038) when started without dietician review. <h3>Conclusion</h3> In this audit, we demonstrated that while symptoms of PEI were present in the majority of patients, the minority of patients were given PERT. The minority of patients were seen by a dietician but when assessed were more likely to receive PERT at the appropriate dosage, which may account for the low rate of PERT in the cohort as a whole. This study highlights the lack of awareness of the problem of PEI in PC patients amongst managing physicians. This could lead to a missed opportunity to reduce symptoms and improve quality of life in patients with a simple intervention. A referral to the dietician was shown to benefit these patients. <h3>Disclosure of interest</h3> None Declared.
THU0279 Evaluation of Plasma Pentraxin-3 Level in Patients with Takayasu's Arteritis
Authors: F. Alibaz-Oner, K. Aksu, S.P. Yentur, G. Keser, G. Saruhan-Direskeneli, H. Direskeneli
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> Assessment of disease activity is one of the major difficulties in patients with TAK during follow-up. To date, no biomarker is universally accepted to be a surrogate for active disease in TAK. In this study, we aimed to investigate plasma Pentraxin-3 (PTX-3) level and its correlation with clinical activity in patients with TAK. <h3>Methods</h3> The study included 94 patients (age: 43.3±13.6 years, F/M: 80/14) with TAK and 40 age and sex matched control subjects (age: 41.5±9.3 years, F/M: 28/12). All patients fulfilled the criteria of American College of Rheumatology (ACR). TAK patients were evaluated by physician9s global assessment (PGA; active/inactive) and Kerr9 criteria (if available). Recently, a new composite index- ITAS2010 (Indian Takayasu Clinical Activity Score) for the clinical assessment of TAK was developed and validated. We also used ITAS2010 to assess clinical activity. Plasma samples were separated to measure PTX-3. Commercial enzyme linked immuno-sorbent assay (ELISA) kits were used for measurements of plasma PTX-3. <h3>Results</h3> Mean disease duration the patients was 6.8±7.2 (0-42) years. Thirty-three (35.5%) patients were clinically active according to PGA. While, Kerr9s activity assessment was available in 79 patients, ITAS2010 was available in 88 patients. Twenty-five (31.6%) patients were active according to the Kerr9s, 28 (31.8%) patients were active according the ITAS2010. Plasma Ptx3 level was significantly higher in TAK compared to healthy controls (3,5±2,5 nanogram (ng)/ml vs. 2,5±1,6 ng/ml, p=0.029). PTX-3 level was found similar between active and inactive patients according to all assessment tools (PGA, Kerr9 and ITAS2010). PTX-3 level significantly correlated with only serum CRP level. PTX-3 level was also similar between taking corticosteroid treatment and not taking. <h3>Conclusions</h3> In our study, plasma PTX-3 level was found significantly higher in TAK compared to healthy controls. But, PTX-3 level was similar between active and inactive patients according to all activity assessment tools such as PGA, Kerr9 and ITAS2010. Our results suggest that plasma PTX-3 level is not discriminatory biomarker for active disease in TAK. <h3>Disclosure of Interest</h3> None declared